The company is headed by CEO Dr. Ravish Sachar, who signed the SEC filing on April 12 and is headquartered in Raleigh.
In January 2020, the company disclosed it had raised some $22 million in SEC filing. In 2018, the company received U.S. Food and Drug Administration (FDA) approval for two systems it designed based on its technology, Integrated Embolic Protection (IEP).
The company was “built on the premise of adding safety to endovascular procedures without compromising performance,” its website reads. Its technology platform “embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes,” according to a company statement.
Earlier this year, the company announced it had hired Steve MacKinnon as its chief commercialization officer. MacKinnon will launch the company’s portfolio of medical devices, according to a statement. He previously served as the vice president of sales at a medical device startup company that was acquired by Boston Scientific.
Previously, the company raised $5 million in 2015. The company did not immediately respond to a request for comment.